According to the Low Dose Naltrexone home page [LDN], LDN has been seen to benefit
colon cancer.
[LDN_Cancer] reports that the late Dr. Bernard Bihari treated approximately 450
patients with some form of cancer, with a 60% success rate, almost all of who had failed to
respond to standard treatments.
According to the Low Dose Naltrexone home page [LDN], LDN has been seen to benefit colon cancer.
It is believed that LDN works by temporarily blocking the body's opioid receptors,
which induces a reflex increase in the body's natural endorphin and enkephalin levels,
which then target the tumors' opioid receptors and induce apoptosis (programmed cell death) of the cancer cells.
The endorphins and enkephalins also increase natural killer cells and other immune responses against the cancer cells
[Mathews1983 🕮 ].
See also [Ma2022 🕮 ]
Dr. Weyrich has been trained to use Low Dose Naltrexone (LDN).
However, Dr. Weyrich has not treated any cases of colon cancer with LDN.
Please see What is Low Dose Naltrexone?
for more information.